{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:03:05Z","timestamp":1789596185504,"version":"build-2803163510"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:p><jats:bold>SETTING:<\/jats:bold> National Center for Tuberculosis and Lung Diseases (NCTLD), Tbilisi, Georgia.<jats:bold>OBJECTIVE:<\/jats:bold> To determine clinical outcomes of patients with tuberculous meningitis (TBM) treated with an intensified regimen including a fluoroquinolone (FQ) and an injectable agent.<jats:bold>DESIGN:<\/jats:bold>\n Prospective cohort of patients aged \u226516 years initiating treatment for TBM at the NCTLD from January 2018 to December 2019. Treatment outcomes and neurologic disability at 1, 6 and 12 months after treatment initiation were assessed.<jats:bold>RESULTS:<\/jats:bold> Among 77 patients with median follow-up\n time of 363 days (IQR 269\u2013374), 97% received a FQ, 62% an injectable agent, 44% linezolid and 39% a carbapenem. Fifty-seven patients (74%) successfully completed treatment, 2 (2.6%) had treatment failure, 6 (7.8%) died, and the remainder (12%) were lost to follow up. Among 11 patients\n treated for multidrug-resistant TBM, the median follow-up time was 467 days and one patient (8%) died. Regarding neurologic outcomes, 14\/76 (18%) patients had Modified Rankin Scores of 0 at baseline, improving to 85% (56\/66) and 94% (47\/50) at 6 and 12 months, respectively.<jats:bold>CONCLUSION:<\/jats:bold>\n Intensified multidrug treatment regimens including a FQ and an injectable agent in all patients and newly implemented drugs in patients with multidrug-resistant TBM resulted in low mortality and favorable neurologic outcomes.<\/jats:p>","DOI":"10.5588\/ijtld.21.0159","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T04:41:56Z","timestamp":1627706516000},"page":"632-639","source":"Crossref","is-referenced-by-count":16,"title":["Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens"],"prefix":"10.5588","volume":"25","author":[{"given":"A. G. C.","family":"Smith","sequence":"first","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gujabidze","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Avaliani","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M.","family":"Blumberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, Departments of Epidemiology and Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sabanadze","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bakuradze","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Avaliani","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. R.","family":"Kempker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kipiani","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia, The University of Georgia, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2021\/00000025\/00000008\/art00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T04:42:02Z","timestamp":1627706522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.21.0159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,1]]}},"alternative-id":["1027-3719(20210801)25:8L.632;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.21.0159","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,1]]}}}